Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Racial underrepresentation in dermatological datasets leads to biased machine learning models and inequitable healthcare
41
Zitationen
4
Autoren
2022
Jahr
Abstract
Objective: Clinical applications of machine learning are promising as a tool to improve patient outcomes through assisting diagnoses, treatment, and analyzing risk factors for screening. Possible clinical applications are especially prominent in dermatology as many diseases and conditions present visually. This allows a machine learning model to analyze and diagnose conditions using patient images and data from electronic health records (EHRs) after training on clinical datasets but could also introduce bias. Despite promising applications, artificial intelligence has the capacity to exacerbate existing demographic disparities in healthcare if models are trained on biased datasets. Methods: Through systematic literature review of available literature, we highlight the extent of bias present in clinical datasets as well as the implications it could have on healthcare if not addressed. Results: We find the implications are worsened in dermatological models. Despite the severity and complexity of melanoma and other dermatological diseases as well as differing disease presentations based on skin-color, many imaging datasets underrepresent certain demographic groups causing machine learning models to train on images of primarily fair-skinned individuals leaving minorities behind. Conclusion: In order to address this disparity, research first needs to be done investigating the extent of the bias present and the implications it may have on equitable healthcare.
Ähnliche Arbeiten
Dermatologist-level classification of skin cancer with deep neural networks
2017 · 13.487 Zit.
Tumor Angiogenesis: Therapeutic Implications
1971 · 10.112 Zit.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
2011 · 7.672 Zit.
Pembrolizumab versus Ipilimumab in Advanced Melanoma
2015 · 5.808 Zit.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
2017 · 5.362 Zit.